Amneal Pharmaceuticals Inc Ordinary Shares - Class A AMRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers
Amneal Reports Third Quarter 2026 Financial Results
Amneal to Report Third Quarter 2026 Results on November 3, 2026
Ipsen Shares Fall After Early Launch of U.S. Generic Rival
Stocks to Watch: Paramount Skydance, Warner Bros. Discovery, Accenture, Amneal Pharmaceuticals
Amneal Gets FDA Approval for Generic Hormone Drug
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Trading Information
- Previous Close Price
- $21.23
- Day Range
- $20.75–21.23
- 52-Week Range
- $11.39–22.07
- Bid/Ask
- $20.83 / $21.24
- Shares Outstanding
- 348.41M
- Market Cap
- $7.36B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 27.24
- Price/Sales
- 2.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 8,500
- Website
- https://www.amneal.com
Valuation
Metric | AMRX |
|---|---|
Price/Earnings (Normalized) | 27.24 |
Price/Book Value | 13.85 |
Price/Sales | 2.20 |
Price/Cash Flow | 11.67 |
Price/Earnings
AMRX
Financial Strength
Metric | AMRX |
|---|---|
Quick Ratio | 1.16 |
Current Ratio | 1.87 |
Interest Coverage | 1.99 |
Quick Ratio
AMRX
Profitability
Metric | AMRX |
|---|---|
Return on Assets (Normalized) | 8.71% |
Return on Equity (Normalized) | 511.17% |
Return on Invested Capital (Normalized) | 19.25% |
Return on Assets
AMRX
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|S%&?bB< | LOCK|#@&? | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|K#WgD<t | LOCK|ckg? | $49B | |||
| Haleon PLC ADR HLN | LOCK|jQ@^<Y? | LOCK|!xF | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|$%mzPDM | LOCK|XGR | $34B | |||
| Viatris Inc VTRS | LOCK|zWPsT& | LOCK|&^ | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|S! | LOCK|J!< | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|H$#&zj | LOCK|<mv | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|DQtq>! | LOCK|k@ | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|w&%S%v! | LOCK|jKYht | $2B | |||
| Perrigo Co PLC PRGO | LOCK|qq%sFNL | LOCK|nm> | $2B |